Innovent Biologics Partners with Takeda for Global Cancer Therapy Development

Innovent Biologics ( (HK:1801) ) has provided an announcement.

Innovent Biologics has entered a global strategic collaboration with Takeda Pharmaceuticals to accelerate the development of its next-generation cancer therapies, including late-stage investigational medicines IBI363 and IBI343, and an early-stage program IBI3001. This collaboration involves co-development and commercialization efforts, with Takeda taking the lead in the U.S. and holding exclusive rights outside of Greater China. Innovent will receive a $1.2 billion upfront payment, with potential milestones totaling up to $11.4 billion. This partnership is expected to enhance Innovent’s global market presence and offer significant financial benefits.

The most recent analyst rating on (HK:1801) stock is a Hold with a HK$96.00 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.

More about Innovent Biologics

Innovent Biologics, Inc. is a biotechnology company focused on the development and commercialization of innovative therapies primarily in the field of oncology. The company is known for its work on next-generation immuno-oncology (IO) and antibody-drug conjugates (ADC), targeting the global market for cancer treatments.

Average Trading Volume: 19,829,794

Technical Sentiment Signal: Buy

Current Market Cap: HK$147.5B

For detailed information about 1801 stock, go to TipRanks’ Stock Analysis page.